Acute Coronary Syndromes Management and Assessment Quiz

A marker of myocardial damage, specifically muscle injury, often elevated in the blood during acute coronary events.

Provides immediate information on heart function and detects abnormalities such as ST-segment changes indicative of myocardial damage.

A specific ECG finding indicating myocardial injury, commonly seen in acute myocardial infarction.

Chest pain or discomfort typically triggered by physical exertion or stress and relieved by rest or nitroglycerin.

Highly sensitive and specific for myocardial injury, often detected in the blood within hours of injury and remaining elevated for days.

Immediate intervention to open blocked arteries, restoring blood flow to the heart muscle.

Dilates blood vessels to improve blood flow to the heart, relieving chest pain.

Irregular heartbeats that can be life-threatening, often occurring after myocardial infarction due to damaged heart tissue.

Reduces workload on the heart, lowering oxygen demand and decreasing the risk of further ischemia or infarction.

Dissolves blood clots by activating plasminogen to form plasmin, breaking down fibrin and dissolving clots.

A risk factor that can be changed or controlled, contributing to the development of acute coronary syndromes.

Reduces cholesterol levels, stabilizes atherosclerotic plaques, and decreases the risk of cardiovascular events.

Predicts the likelihood of adverse cardiac events based on specific risk factors.

Unstable angina typically presents with chest pain lasting less than 30 minutes, often occurring at rest or with minimal exertion.

Elevated levels indicate heart failure and are not specific to myocardial infarction, rising later in the event.

An alternative antiplatelet medication to reduce the risk of blood clots in patients allergic to aspirin.

Factors such as age, heart rate, blood pressure, creatinine, and signs of heart failure are considered in the GRACE risk score, but history of coronary artery disease is not included.

Reduces the risk of stent thrombosis and recurrent cardiovascular events following PCI, typically continued for 12 months.

Blocks the final common pathway of platelet aggregation, reducing the risk of thrombus formation and ischemic events.